VVP
ESPR

Venture Visionary Partners’s Esperion Therapeutics ESPR Stock Holding History

Venture Visionary Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,223
Closed -$32.4K – 672
2025
Q3 		$32.4K Buy
12,223
+1,848
+18% +$3.57K ﹤0.01% 624
2025
Q2 		$10.2K Hold
10,375
– – ﹤0.01% 610
2025
Q1 		$14.9K Hold
10,375
– – ﹤0.01% 574
2024
Q4 		$22.8K Hold
10,375
– – ﹤0.01% 541
2024
Q3 		$17.1K Hold
10,375
– – ﹤0.01% 541
2024
Q2 		$23K Hold
10,375
– – ﹤0.01% 548
2024
Q1 		$27.8K Buy
+10,375
New +$25.2K ﹤0.01% 548
2022
Q3 		– Sell
-7,830
Closed -$49.8K – 800
2022
Q2 		$49.8K Buy
+7,830
New +$44.4K ﹤0.01% 802

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Venture Visionary Partners's ESPR Position: Q4 2025 in Review

Venture Visionary Partners sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 12,223 shares — an estimated $32.4K sold.

Venture Visionary Partners first reported a position in ESPR in Q2 2022 and held it in 8 quarters. The position peaked at $49.8K in Q2 2022. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Venture Visionary Partners reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Venture Visionary Partners sold 12,223 Esperion Therapeutics shares in Q4 2025, an estimated $32.4K.
  • Venture Visionary Partners first reported a position in Esperion Therapeutics in Q2 2022 and held it in 8 quarters.
  • Venture Visionary Partners's Esperion Therapeutics position peaked at $49.8K in Q2 2022.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Venture Visionary Partners's 13F filing for Q4 2025, filed 13 Feb 2026.